Under construction – not a live service
Sign in

NCT07625306WithdrawnPhase 3

Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL

A Randomized, Double-blind, Placebo-controlled, Multicenter Study Evaluating the Efficacy, Safety, Tolerability, and Coronary Plaque Effects of Early Pelacarsen (TQJ230) Initiation in Patients in the US With Elevated Lp(a) and Recent Acute Coronary Syndrome

Source: ClinicalTrials.gov · Last updated 14 Oct 2026

Reason given: Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint

Brief summary (registry, in English)

CTQJ230A1US13 is a randomized, double-blind, placebo-controlled, multicenter phase IIIb study designed to evaluate the efficacy, safety, tolerability, and coronary plaque effects of early pelacarsen (TQJ230) initiation in participants with elevated Lp(a) and recent acute coronary syndrome (ACS).

Status (registry)
Withdrawn
Phase (registry)
Phase 3
Study type
Interventional
Enrollment
0 (actual)
First submitted
27 May 2026
Start date
1 Sept 2026
Primary completion date
22 Jan 2029
Lead sponsor
Novartis Pharmaceuticals
NCT number
NCT07625306

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Uncontrolled hypertension
  • Heart failure New York Heart Association (NYHA) class IV
  • History of malignancy of any organs
  • History of hemorrhagic stroke or other major bleeding
  • Active liver disease or hepatic dysfunction
  • Significant kidney disease
  • Contraindication for CCTA or severe contrast allergy

Lab values

  • Platelet count ≤ LLN

Other

  • Pregnant or nursing women
    • Other protocol-defined inclusion/exclusion criteria may apply

Who the study is looking for

  • Lp(a) ≥ 150 nmol/L
  • Within 10 days of hospitalization for ACS event and meets all of the following criteria:
  • Clinical syndrome consistent with spontaneous cardiac ischemia
  • Diagnosis of ACS: ST-elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI)

Age in the registry: 18 years to 79 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.